Your AI-Trained Oncology Knowledge Connection!

Frank J. Brescia, MD

home / authors / frank-j-brescia-md

Articles

Irinotecan/Gemcitabine Combination Chemotherapy in Pancreatic Cancer

Caio Max S. Rocha Lima, MD;Carol A. Sherman, MD;Frank J. Brescia, MD;Chris Y. Brunson, MD;Mark R. Green, MD

March 2nd 2001

Gemcitabine (Gemzar) and irinotecan (CPT-11, Camptosar) are active cytotoxic drugs against pancreatic cancer. Preclinical data evaluating the combination of gemcitabine and irinotecan suggest dose-dependent synergistic

Docetaxel Followed by Gemcitabine and Irinotecan in Solid Tumors

Caio Max S. Rocha Lima, MD;Carol A. Sherman, MD;Frank J. Brescia, MD;Mark R. Green, MD

January 1st 2001

Docetaxel (Taxotere), gemcitabine (Gemzar), and irinotecan (Camptosar, CPT-11) are active single agents in a variety of solid tumors. In combination, synergism may be schedule dependent. Preclinical studies suggested

Irinotecan in the Management of Patients With Pancreatic Cancer

Mark R. Green, MD;Melinda Harper, RN;Ahmad R. Safa, MD, PhD;Carol A. Sherman, MD;Chaudry M. Mushtaq, MD;Hamid Bahadori, MD;Frank J. Brescia, MD;Caio Max S. Rocha Lima, MD

December 3rd 2000

Synergy with no overlapping toxicities has been demonstrated for the combination of irinotecan ( Camptosar, CPT-11) and gemcitabine (Gemzar) in vitro. Results of a single-institution phase I study in which patients with